Sorafenib for the treatment of breast cancer

References

• Ferlay J, Soerjomataram I, Ervik M, et al., Cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. [cited 2016 Nov 15]. Available from: http://globocan.iarc.fr ​​​​
   Google Scholar
• Autier P, Boniol M, La Vecchia C, et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ. 2010;341:c3620.
   PubMed Web of Science ®Google Scholar
• Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385:977–1010.
   PubMed Web of Science ®Google Scholar
• Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v8–30.
   PubMed Web of Science ®Google Scholar
• Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432–444.
   PubMed Web of Science ®Google Scholar
• Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer. Ann Oncol. 2015;26:1533–1546.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol. 2014;25:1871–1888.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012;21:242–252.
   PubMed Web of Science ®Google Scholar
• Cortes J, O’Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914–923.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–7803.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009;27:3611–3619.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Bedard PL, Winer EP, et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2009;10:1174–1181.
   Google Scholar
• Kristensen TB, Knutsson ML, Wehland M, et al. Anti-vascular endothelial growth factor therapy in breast cancer. Int J Mol Sci. 2014;15:23024–23041.
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–2676.
   PubMed Web of Science ®Google Scholar
• Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28:3239–3247.
   PubMed Web of Science ®Google Scholar
• Wehland M, Bauer J, Infanger M, et al. Target-based anti-angiogenic therapy in breast cancer. Curr Pharm Des. 2012;18:4244–4257.
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366:299–309.
   PubMed Web of Science ®Google Scholar
• Miles DW, Diéras V, Cortés J, et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol. 2013;24:2773–2780.
   PubMed Web of Science ®Google Scholar
• Mackey J, Oguz A, Rahatli S, et al. TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer. Clin Breast Cancer. 2009;9:258–261.
   PubMed Web of Science ®Google Scholar
• Mackey JR, Ramos-Vazquez M, Lipatov O, et al. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. J Clin Oncol. 2015;33:141–148.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Elias AD, Rugo HS, et al. Phase-II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008;26:1810–1816.
   PubMed Web of Science ®Google Scholar
• Bergh J, Bondarenko IM, Lichinitser MR, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase-III study. J Clin Oncol. 2012;30:921–929.
   PubMed Web of Science ®Google Scholar
• Barrios CH, Liu MC, Lee SC, et al. Phase-III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat. 2010;121:121–131.
   PubMed Web of Science ®Google Scholar
• Robert NJ, Saleh MN, Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase-III, randomized, open-label trial. Clin Breast Cancer. 2011;11:82–92.
   PubMed Web of Science ®Google Scholar
• Crown JP, Diéras V, Staroslawska E, et al. Phase-III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol. 2013;31:2870–2878.
   PubMed Web of Science ®Google Scholar
• Mayer EL, Dhakil S, Patel T, et al. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol. 2010;21:2370–2376.
   PubMed Web of Science ®Google Scholar
• Chemistry Review for Sorafenib. [cited 2016 Nov 15]. Available from: http://www.accessdata. fda.gov/ drugsatfda_ docs/nda/2005/021923_s000_Nexavar_ChemR.pdf
   Google Scholar
• Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;58:35–44.
   Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109.
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006;98:326–334.
   PubMed Web of Science ®Google Scholar
• Fumarola C, Caffarra C, La Monica S, et al. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling. Breast Cancer Res Treat. 2013;141:67–78.
   PubMed Web of Science ®Google Scholar
• Bonelli MA, Fumarola C, Alfieri RR, et al. Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res Treat. 2010;124:79–88.
   PubMed Web of Science ®Google Scholar
• Pedersen AM, Thrane S, Lykkesfeldt AE, et al. Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor α. Int J Oncol. 2014;45:2167–2175.
   PubMed Web of Science ®Google Scholar
• Valabrega G, Capellero S, Cavalloni G, et al. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Res Treat. 2011;130:29–40.
   PubMed Web of Science ®Google Scholar
• Kacan T, Altun A, Altun GG, et al. Investigation of antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells. Asian Pac J Cancer Prev. 2014;15:3185–3189.
   PubMedGoogle Scholar
• Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol. 2005;16:1688–1694.
   PubMed Web of Science ®Google Scholar
• Kane RC, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006;12:7271–7278.
   PubMed Web of Science ®Google Scholar
• Peer CJ, Sissung TM, Kim A, et al. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res. 2012;18:2099–2107.
   PubMed Web of Science ®Google Scholar
• Van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35:692–706.
   PubMed Web of Science ®Google Scholar
• Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965–972.
   PubMed Web of Science ®Google Scholar
• Hu S, Chen Z, Franke R, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009;15:6062–6069.
   PubMed Web of Science ®Google Scholar
• Gnoth MJ, Sandmann S, Engel K, et al. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein. Drug Metab Dispos. 2010;38:1341–1346.
   PubMed Web of Science ®Google Scholar
• Haouala A, Rumpold H, Untergasser G, et al. siRNA-mediated knock-down of P-glycoprotein expression reveals distinct cellular disposition of anticancer tyrosine kinases inhibitors. Drug Metab Lett. 2010;4:114–119.
   PubMedGoogle Scholar
• Lagas JS, Van Waterschoot RA, Sparidans RW, et al. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010;9:319–326.
   PubMed Web of Science ®Google Scholar
• Singhal SS, Sehrawat A, Sahu M, et al. Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010;126:1327–1338.
   PubMed Web of Science ®Google Scholar
• Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009;69:223–240.
   PubMed Web of Science ®Google Scholar
• Luu T, Frankel P, Chung C, et al. Phase I/II trial of vinorelbine and sorafenib in metastatic breast cancer. Clin Breast Cancer. 2014;14:94–100.
   PubMed Web of Science ®Google Scholar
• Yardley DA, Frankel P, Chung C, et al. Sorafenib plus ixabepilone as first-line treatment of metastatic her2-negative breast cancer: a Sarah Cannon Research Institute phase I/II trial. Clin Breast Cancer. 2016;16:180–187.
   PubMed Web of Science ®Google Scholar
• Isaacs C, Herbolsheimer P, Liu MC, et al. Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treat. 2011;125:137–143.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Identifier: NCT00634634. [cited 2016 Nov 15. Available from: https://clinicaltrials.gov/ct2/show/NCT00634634
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01724606. [cited 2016 Nov 15. Available from: https://clinicaltrials.gov/ct2/show/NCT01724606
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01621906. [cited 2016 Nov 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT01621906
   Google Scholar
• Moreno-Aspitia A, Morton RF, Hillman DW, et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol. 2009;27:11–15.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Loibl S, Zamagni C, et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs. 2009;20:616–624.
   PubMed Web of Science ®Google Scholar
• Mina LA, Yu M, Johnson C, et al. A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109. Invest New Drugs. 2013;3:1307–1310.
   Web of Science ®Google Scholar
• ClinicalTrials.gov Identifier: NCT02624700. [cited 2016 Nov 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02624700
   Google Scholar
• Massarweh S, Moss J, Wang C, et al. Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer. Future Oncol. 2014;10:2435–2448.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Hainsworth JD, Burris HA, et al. A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer. Clin Adv Hematol Oncol. 2011;9:280–286.
   PubMedGoogle Scholar
• Loibl S, Rokitta D, Conrad B, et al. Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA. Breast Care (Basel). 2014;9:169–174.
   PubMed Web of Science ®Google Scholar
• Bazzola L, Foroni C, Andreis D, et al. Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. Br J Cancer. 2015;112:52–60.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Kaklamani V, Sahoo TP, et al. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur J Cancer. 2013;49:312–322.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Identifier: NCT00622466. [cited 2016 Nov 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT00622466
   Google Scholar
• Baselga J, Zamagni C, Gomez P, et al. A phase III randomized, double-blind, trial comparing sorafenib plus capecitabine versus placebo plus capecitabine in the treatment of locally advanced or metastatic HER2-negative breast cancer. Ann Oncol. 2014;25:Abstract LBA8.
   Google Scholar
• Mariani G, Burdaeva O, Roman L, et al. A double-blind, randomized phase lib study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with docetaxel and/or letrozole in patients with metastatic breast cancer (MBC): FM-B07-01trial. Eur J Cancer. 2011;47(Suppl 2):10.
   Google Scholar
• Baselga J, Piccart-Gebhart M, Holmes E, et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol. 2012;30:1484–1491.
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Furuse M, Nonoguchi N, et al. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res. 2013;19:2745–2754.
   PubMed Web of Science ®Google Scholar
• Baselga J, Costa F, Gomez H, et al. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast cancer (the RESILIENCE study): study protocol for a randomized controlled trial. Trials. 2013;14:228.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Identifier: NCT01234337. [cited 2016 Nov 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT01234337
   Google Scholar
• Chen J, Tian CX, Yu M, et al. Efficacy and safety profile of combining sorafenib with chemotherapy in patients with HER2-negative advanced breast cancer: a meta-analysis. J Breast Cancer. 2014;17:61–68.
   PubMed Web of Science ®Google Scholar
• Zafrakas M, Papasozomenou P, Emmanouilides C, Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials. World J Clin Oncol. 2016;7:331–336.
   PubMedGoogle Scholar
• Full prescribing information for Nexavar. [cited 2016 Nov 15]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021923s016lbl.pdf
   Google Scholar
• European public assessment reports. [cited 2016 Nov 15]. Available from: http://ema.europa.eu/Findmedicine/human/medicines/European Public Assessment Reports
   Google Scholar
• Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997 Mar 1;57(5):963–969.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–330.
   PubMed Web of Science ®Google Scholar
• Frentzas S, Simoneau E, Bridgeman VL. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat Med. 2016;22:1294–1302.
   PubMed Web of Science ®Google Scholar
• Ding Q, Huo L, Yang JY, et al. Down-regulation of myeloid cell leukemia-1 through inhibiting erk/pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res. 2008;68(15):6109–6117.
   PubMed Web of Science ®Google Scholar
• Merz M, Komljenovic D, Zwick S, et al. Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases. Eur J Cancer. 2011;47:277–286.
   PubMed Web of Science ®Google Scholar